Participants
mellitus, chronic kidney disease, valve stenosis, bicuspid aortic valve, diabetes
AUTOIMMUNE DISEASES, MALIGNANT NEOPLASMS, INFECTIOUS ENDOCARDITIS, AORTIC VALVE INSUFFICIENCY, DISEASES, FIBRILLATION, DIABETES
This study included patients aged at least 65 years or older, with severe aortic
valve stenosis, with small aortic annulus (≤ 23 mm), and who underwent
isolated aortic valve replacement, divided into two groups - Group P, 12
patients with Perceval™ S valve (LivaNova), and Group C, 12 patients with
conventional bioprosthesis, EpicTM (four patients) and TrifectaTM (eight
patients). The prostheses used in group C were the institution’s routinely used
prostheses that were available at the time of the surgical procedures under
study. The exclusion criteria were pure aortic valve insufficiency, congenital
bicuspid aortic valve, aortic root dilatation, need for associated surgical
procedure, emergency surgery, infectious endocarditis, use of immunosuppressive
drugs or diagnosis of immunosuppressive diseases, reoperation, diabetes
mellitus, autoimmune diseases, chronic kidney disease requiring dialysis, atrial
fibrillation, and malignant neoplasms.